As of 2026-03-26, the Relative Valuation of EyePoint Pharmaceuticals Inc (EYPT) is (43.99) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.05 USD, the upside of EyePoint Pharmaceuticals Inc based on Relative Valuation is -437.1%.
The range of the Relative Valuation is (30.82) - (47.97) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 18.2x | 16.6x |
| Forward P/E multiples | 9.9x - 17.1x | 14.8x |
| Fair Price | (30.82) - (47.97) | (43.99) |
| Upside | -336.2% - -467.6% | -437.1% |
| Date | P/E |
| 2026-03-23 | -4.70 |
| 2026-03-20 | -4.72 |
| 2026-03-19 | -4.92 |
| 2026-03-18 | -4.87 |
| 2026-03-17 | -4.96 |
| 2026-03-16 | -4.80 |
| 2026-03-13 | -4.71 |
| 2026-03-12 | -5.01 |
| 2026-03-11 | -5.33 |
| 2026-03-10 | -5.51 |
| 2026-03-09 | -5.59 |
| 2026-03-06 | -5.62 |
| 2026-03-05 | -5.62 |
| 2026-03-04 | -6.42 |
| 2026-03-03 | -6.54 |
| 2026-03-02 | -6.55 |
| 2026-02-27 | -6.27 |
| 2026-02-26 | -6.37 |
| 2026-02-25 | -6.34 |
| 2026-02-24 | -6.09 |
| 2026-02-23 | -6.09 |
| 2026-02-20 | -5.47 |
| 2026-02-19 | -5.25 |
| 2026-02-18 | -5.13 |
| 2026-02-17 | -5.32 |
| 2026-02-13 | -4.62 |
| 2026-02-12 | -4.64 |
| 2026-02-11 | -4.59 |
| 2026-02-10 | -4.90 |
| 2026-02-09 | -5.02 |
| 2026-02-06 | -4.75 |
| 2026-02-05 | -4.54 |
| 2026-02-04 | -4.40 |
| 2026-02-03 | -4.57 |
| 2026-02-02 | -4.74 |
| 2026-01-30 | -4.83 |
| 2026-01-29 | -5.26 |
| 2026-01-28 | -5.37 |
| 2026-01-27 | -5.64 |
| 2026-01-26 | -5.51 |
| 2026-01-23 | -5.42 |
| 2026-01-22 | -5.83 |
| 2026-01-21 | -5.54 |
| 2026-01-20 | -5.55 |
| 2026-01-16 | -5.38 |
| 2026-01-15 | -5.65 |
| 2026-01-14 | -5.68 |
| 2026-01-13 | -5.69 |
| 2026-01-12 | -5.69 |
| 2026-01-09 | -5.79 |